Novel steroid carbamates reverse multidrug-resistance in cancer therapy and show linkage among efficacy, loci of drug action and P-glycoprotein's cellular localization

European Journal of Pharmaceutical Sciences

Volumn 41, Issue 1, 2010, Pages 53-59

  Argov, Mirit ^a   Bod, Tal ^a   Batra, Satish ^b   Margalit, Rimona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer; Cell membrane p glycoprotein; Intracellular p glycoprotein; Multidrug resistance; Novel chemosensitizers

Indexed keywords

11 CARBAMIC ACID N,N DIBENZYL PROGESTERONE ESTER; 11 CARBAMIC ACID N,N DIBUTYL PROGESTERONE ESTER; CARBAMIC ACID DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; PACLITAXEL; STEROID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL MEMBRANE; CELL NUCLEUS MEMBRANE; CELLULAR DISTRIBUTION; CHEMOSENSITIZATION; COLON CANCER; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG DIFFUSION; HUMAN; HUMAN CELL; KINETICS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; DRUG RESISTANCE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARBAMATES; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN;

EID: 77954763228     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.05.012     Document Type: Article

References (26)

1. Argov M., Kashi R., Peer D., Margalit R. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett. 2009, 274:118-125.
2. Baldini N., Scotlandi K., Serra M., Shikita T., Zini N., Ognibene A., Santi S., Ferracini R., Maraldi N.M. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur. J Cell. Biol. 1995, 68:226-239.
3. Bates S.E. Drug resistance: still on the learning curve. Clin. Cancer Res. 1999, 5:3346-3348.
4. Batra S., Karlsson R., Witt L. Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells. Int. J. Cancer 1996, 68:644-649.
5. Calcabrini A., Meschini S., Stringaro A., Cianfriglia M., Arancia G., Molinari A. Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells. Histochem. J. 2000, 32:599-606.
6. Coley H.M., Verrill M.W., Gregson S.E., Odell D.E., Fisher C., Judson I.R. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur. J. Cancer 2000, 36:881-888.
7. Elron-Gross I., Glucksam Y., Melikhov D., Margalit R. Cyclooxygenase inhibition by diclofenac formulated in bioadhesive carriers. Biochim. Biophys. Acta 2008, 1778:931-936.
8. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
9. Koziara J.M., Lockman P.R., Allen D.D., Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release 2004, 99:259-269.
10. Lee H., Lee S.I., Cho J., Choi S.U., Yang S.I. Synthesis and in vitro evaluation of 1,8-diazaanthraquinones bearing 3-dialkylaminomethyl or 3-(N-alkyl- or N-aryl)carbamoyloxymethyl substituent. Eur. J. Med. Chem. 2003, 38:695-702.
11. Leontieva O.V., Preobrazhenskaya M.N., Bernacki R.J. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate. Invest. New Drugs 2002, 20:35-48.
12. Litman T., Druley T.E., Stein W.D., Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. 2001, 58:931-959.
13. Molinari A., Calcabrini A., Meschini S., Stringaro A., Crateri P., Toccacieli L., Marra M., Colone M., Cianfriglia M., Arancia G. Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells. Curr. Protein Pept. Sci. 2002, 3:653-670.
14. Molinari A., Calcabrini A., Meschini S., Stringaro A., Del Bufalo D., Cianfriglia M., Arancia G. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. Int. J. Cancer 1998, 75:885-893.
15. Molinari A., Cianfriglia M., Meschini S., Calcabrini A., Arancia G. P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. Int. J. Cancer 1994, 59:789-795.
16. Ohishi K., Morinaga Y., Ohsumi K., Nakagawa R., Suga Y., Tsuji T., Akiyama Y., Tsuruo T. Potentiation of antitumor and antimetastatic activities of adriamycin by a novel N-alkylated dihydropyridine, AC394 and its enantiomers in colon cancer-bearing mice. Cancer Chemother. Pharmacol. 1996, 38:446-452.
17. Peer D., Dekel Y., Melikhov D., Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004, 64:7562-7569.
18. Peer D., Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006, 237:180-187.
19. Pusztai L., Wagner P., Ibrahim N., Rivera E., Theriault R., Booser D., Symmans F.W., Wong F., Blumenschein G., Fleming D.R., Rouzier R., Boniface G., Hortobagyi G.N. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005, 104:682-691.
20. Robey R.W., Shukla S., Finley E.M., Oldham R.K., Barnett D., Ambudkar S.V., Fojo T., Bates S.E. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem. Pharmacol. 2008, 75:1302-1312.
21. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
22. Tahir S.K., Han E.K., Credo B., Jae H.S., Pietenpol J.A., Scatena C.D., Wu-Wong J.R., Frost D., Sham H., Rosenberg S.H., Ng S.C. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. 2001, 61:5480-5485.
23. Trock B.J., Leonessa F., Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst. 1997, 89:917-931.
24. Uchiyama-Kokubu N., Watanabe T. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance. Anticancer Drugs 2001, 12:769-779.
25. Watanabe T., Naito M., Kokubu N., Tsuruo T. Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies. J. Natl. Cancer Inst. 1997, 89:512-518.
26. Xiao J.J., Huang Y., Dai Z., Sadee W., Chen J., Liu S., Marcucci G., Byrd J., Covey J.M., Wright J., Grever M., Chan K.K. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J. Pharmacol. Exp. Ther. 2005, 314:467-475.